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Abstract
Background: Primary effusion lymphoma (PEL) is a rare KSHV/HHV8-associated high-grade non-Hodgkin’s
lymphoma (NHL) of B-cell origin, characterized by serous effusions in body cavities. Most patients are HIV-infected
men with severe immunosuppression and other HHV8-associated diseases such as Kaposi’s sarcoma (KS). The
prognosis for those infected is poor, with a median survival of less than 6 months in most cohorts. Sustained
complete remission is rare. High-dose chemotherapy regimens are used to improve remission rate and survival.
The aim of the present study was to compare the drug sensitivity pattern of the available primary effusion (body
cavity based) lymphoma-derived cell lines in order to find additional, potentially effective drugs that are not
included in current chemotherapy treatment protocols.
Methods: We have analyzed 11 cell lines against 27 frequently used cytostatic drugs in short term (3 days) survival
assays using automated high throughput confocal microscopy.
Results: All cell lines showed a distinct, individual drug sensitivity pattern. Considering the in vitro used and
clinically achieved drug concentration, Vinorelbine, Paclitaxel, Epirubicin and Daunorubicin were the most effective
drugs.
Conclusions: We suggest that inclusion of the above drugs into PEL chemotherapy protocols may be justified. The
heterogeneity in the drug response pattern however indicated that assay-guided individualized therapy might be
required to optimize therapeutic response.
Background
Human herpesvirus 8 (HHV8) or Kaposi sarcoma her-
pesvirus (KSHV) is the probable causative agent of two
distinct lymphoproliferative disorders: primary effusion
lymphoma (PEL) and the plasma cell variant of multi-
centric Castleman disease (MCD) in addition to Kaposi
sarcoma (KS) [1].
Primary effusion lymphoma (PEL), or alternatively:
body cavity lymphoma is a non-Hodgkin’s lymphoma
(NHL) of B-cell origin that develops predominantly in
the serous body cavities [2]. The lymphoma cells,
although lacking many conventional B-cell markers,
carry immunoglobulin gene rearrangement and express
syndecans, suggesting pre-plasma cell origin. At the
clinico-pathological level, PEL is characterized by liquid
growth in the serous body cavities associated with
spreading along the serous membranes without infiltra-
tive or destructive growth patterns [3,4]. Morphologi-
cally, PEL bridges immunoblastic and anaplastic features
and frequently displays a certain degree of plasmacell
differentiation. In all known cases, the monoclonal B-
cell population is infected with HHV-8. Half of the lym-
phomas are dually infected with HHV-8 and Epstein-
Barr virus (EBV) [5]. In the context of AIDS, most cases
are associated with other KSHV/HHV8-related diseases
such as Kaposi’s sarcoma (KS) or multicentric Castle-
man’s disease (MCD). As PEL typically lacks a solid
component, its diagnosis rests on the cytological exami-
nation of body fluid. Phenotypically, expression of the
CD45 antigen (> 90% of cases) confirms the lymphoid
derivation of PEL cells, which exhibit an indeterminate
immunophenotype, as they usually lack expression of B-
and T-cell associated antigens (the majority of cases
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reported). There are, however, cases in the literature
that had a B-cell or T-cell phenotype respectively [1].
Conversely, PEL cells generally express various mar-
kers associated with activation, including CD30
(approximately 75% of cases), CD38, CD71 and the
epithelial membrane antigen. Moreover, PEL cells
express several plasma cell markers including CD138,
VS38c and MUM-1/IRF4 [1].
The prognosis of PEL is poor, as the median survival
in the previously published series does not exceed 3
months [3,6-10].
Given its rarity, however, there are very few longitudi-
nal observational series of patients with PEL and no
large prospective trials have ever defined optimal treat-
ment strategies [11].
Prior to the introduction of antiretroviral therapy, the
therapeutic results were unsatisfactory in cohorts of
HIV+ patients, despite the use of aggressive polyche-
motherapy regimens including anthracyclines. The sig-
nificant improvement in the prognosis of AIDS-related
lymphomas observed in the antiretroviral therapy era
also applies to the PEL setting.
In addition, the routine use of growth factors, such as
the granulocyte colony-stimulating factor (G-CSF), to
avoid prolonged periods of neutropenia resulting from
chemotherapy is standard practice for all AIDS-related
lymphoma (ARL) patients.
Despite the improvement in therapeutical strategies
during the last few years, there is no evidence of a cure
for PEL patients with conventional systemic chemother-
apy addressed to aggressive NHL. The suggested benefit
of high-dose Methotrexate in association with CHOP
(Cyclophosphamide, Doxorubicin, Prednisolone and
Vincristine)-like regimens is negatively balanced by the
hampered toxicity of Methotrexate in the presence of
serous effusions [1].
Novel approaches for body cavity lymphoma therapy
outside traditional chemotherapy have been suggested as
well [11]. These include the addition of antiviral therapy
as well as inhibition of specific cellular targets. Anti-
tumor activity of the antiviral therapy directed against
KSHV/HHV8 infection has been reported. This experi-
ence is based on single case reports. Patients with a
diagnosis of PEL, related or not to HIV infection,
experienced prolonged complete remission after the
intracavitary administration of Cidofovir - an antiviral
agent. Intracavitary Cidofovir, as well as interferon-a,
may represent a reasonable choice in patients’ refractory
to conventional chemotherapy, or in elderly patients not
eligible for more toxic systemic therapies [12].
Another approach may be to target NF-B through
the use of proteasome inhibition with drugs, such as
Bortezomib that induces apoptosis of PEL cell lines in
vitro [13].
In the present study we have investigated 11 different
primary effusion (body cavity based) lymphoma-derived
cell lines to compare the drug sensitivity pattern, in
order to find new potentially successful chemotherapy
agents, that are not used in current treatment
protocols.
Methods
Cell lines and culture conditions
The following primary effusion (body cavity based) lym-
phoma-derived cell lines were used in the present study.
CRO-AP/2, CRO-AP/5, CRO-AP/6, BC-2, BC-3 were
established from pleural effusion, CRO-AP/3, HBL-6,
BC-3, BCBL-1, JSC-1 were established from ascites fluid
and BCP-1 from peripheral blood.
Body-cavity cell lines were cultured in IMDM (Sigma),
supplemented with 20% heat-inactivated (at 56°C for 45
min) fetal calf serum (FCS, Sigma), 100 IU/ml penicillin
(Sigma), 100 μg/ml streptomycin (Sigma) and 2 mM L-
glutamine (Sigma). Cell lines were grown at 37°C in the
presence of 5% CO2. Cultures were fed twice weekly
with the above-mentioned medium; maintained at ca.
0.5 × 106 cells/ml. All cell lines were examined daily in
their culture vessels under an inverted microscope.
Absence of mycoplasma contamination was routinely
assessed using staining with Hoechst 33258.
In vitro drug sensitivity assay
In vitro drug resistance of body-cavity cell lines were
assessed using a 3-day cell culture on microtiter plates.
27 drugs (Table 1) were tested, each at 4 different con-
centrations in triplicates on 384 well plates. Each well
was loaded with 30 μl cell suspension containing 9000
cells. After three days of incubation the living and dead
cells were differentially stained using fluorescent Vital-
Dye (Biomarker Hungary). The precise number of living
and dead cells was determined using a custom built-
automated laser confocal fluorescent microscope (a
modified Perkin-Elmer UltraView LCI) at the Karolinska
Institute core Visualization Facility (KIVIF). The images
were captured using the computer program QuantCap-
ture 4.0 [14,15]. Image correction and counting of living
and dead cells was carried out by the program Quant-
Count 5.0. All programs were created by the authors,
using the symbol based graphical programming environ-
ment OpenLab Automaton (Improvision). The 15 con-
trol wells, that were used to determine the control cell
survival (CCS), contained cells with only culture med-
ium and 50 nl DMSO without drugs. 5 wells contained
cells with culture medium alone. Comparing the two
types of control wells no toxic effect of DMSO could be
seen. Mean cell survival (MCS) was determined from
the average of cell survival of all 11 body-cavity cell
lines (Table 2).
Ötvös et al. BMC Cancer 2011, 11:441
http://www.biomedcentral.com/1471-2407/11/441
Page 2 of 11
Drugs
For the in vitro drug sensitivity test 27 drugs were used
(summarized in Table 1). All the drugs were dissolved
in 50% dimethyl sulfoxide (DMSO) - 50% phosphate
buffered saline (PBS) and were printed on the 384 well
plates using high-density array replicator metal pins
with 50 nl replica volumes in a Biomek 2000 fluid dis-
penser robot (Beckman). The same robot was used to
generate the drug masterplates containing the triplicates
of four different drug dilutions (1 ×, 5 ×, 25 ×, 125 ×)
using a single tip automatic pipettor dispenser head.
The starting concentration of the dilution series for the
individual drugs was initially determined based on the
solubility of the different agents.
The drug plates that were used in this study were also
tested on a large number of in vitro tumor cell lines and
cells from primary tumor samples. In these assays we
could show that it was possible to find sensitive cell
lines for each individual drug, demonstrating that all the
drugs on the plate were active [16,17] (data not shown).
To calculate the relationship between the in vitro drug
concentrations and the in vivo ones, we used area under
curve (AUC; area under the plasma, concentration curve
versus time) values of the individual drugs. For this com-
parison Quotient of Area Under Curve values (QAUC72
hr) were determined by the following formula:
in vitro used concentration × 72 hours(µg× hr/ml)/in vivo AUC72hr(µg× h/ml)
The in vivo AUC72 hr corresponds to the area under
curve value achieved in patients under a 72 hours per-
iod. The in vivo AUC72 hr was established from the
Table 1 Chemotherapic agents used in the present study
Clinical
dose
Half
time
In vivo
AUC72
hr
In vitro used
concentrations
In vitro
AUC72 hr
Ref QAUC
Antimetabolites Folic acid Methotrexate 12 g/m2 24 623,70 0,033 - 4,17 12,000-1499,976 [21] 0,019 - 2,405
Purine Cladribine 5 mg/m2 3 5,67 0,007 - 0,83 0,480-59,976 [22] 0,085-10,578
Fludarabine 25 mg/m2 2 27,72 0,167 - 20,83 12,000-1499,976 [23] 0,433-54,112
6-Mercaptopurin 85 mg/m2 4 138,60 0,556 - 69,44 39,997-4999,680 [24] 0,289-36,073
Pyrimidine Cytarabine 1 g/m2 2 221,76 0,133 - 16,66 9,596-1199,520 [25] 0,043-5,409
Fluorouracil 400 mg/m2 0.25 69,30 0,333 - 41,66 23,996-2999,520 [26] 0,346-43,283
Gemcitabine 1000 mg/m2 0.7 388,08 0,267 - 33,33 19,198-2399,760 [27] 0,049-6,184
Alkylating/alkylating-like Nitrogen
mustards
Chlorambucil 0.2 mg/m2 2 33,60 0,667 - 83,33 47,998-5999,760 [28] 1,429-178,564
Platinum Carboplatin 360 mg/m2 3 665,28 0,007 - 0,83 0,480-59,976 [29] 0,001-0,090
Oxaliplatin 130 mg/m2 5.74 270,46 0,033 - 4,17 2,400-299,952 [30] 0,009-1,109
Spindle poison/mitotic
inhibitor
Taxane Docetaxel 85 mg/m2 0.6 24,95 0,067 - 8,33 4,798-599,760 [31] 0,192-24,040
Paclitaxel 175 mg/m2 3 257,80 0,013 - 1,67 0,956-119,520 [27] 0,004-0,464
Vinca Vinblastin 1.7 mg/m2 0.83 1,71 0,00067 - 0,083 0,048-5,998 [32] 0,028-3,510
Vincristine 1.32 mg/m2 2 1,55 0,00067 - 0,083 0,480-59,976 [33] 0,309-38,636
Vinorelbine 80 mg/m2 40 498,96 0,007 - 0,83 4,798-599,760 [34] 0,010-1,202
Cytotoxic/antitumor
antibiotics
Anthracyclin Daunorubicin 1.5 mg/kg 18 531,56 0,033 - 4,17 2,400-299,952 [35] 0,005-0,564
Doxorubicin 50 mg/m2 30 1091,48 0,013 - 1,66 0,956-119,520 [36] 0,001-0,110
Epirubicin 90 mg/m2 15 604,21 0,013 - 1,66 0,960-119,952 [27] 0,002-0,199
Streptomyces Dactinomycin 1.5 mg/m2 36 8,98 0,003 - 0,42 0,240-29,995 [37] 0,027-3,340
Bleomycin 8 IU/kg/day 6 33,26 0,008 - 1 0,576-72,000 [38] 0,017-2,165
Mitomycin 20 mg/m2 1 4,44 0,003 - 0,33 0,317-39,600 [39] 0,071-8,929
Hydroxyurea 15 mg/m2 2 630,00 0,333 - 41,66 23,996-2999,520 [40] 0,038-4,761
Topo-isomerase in-
hibitors
Camptotheca Topotecan 1.2 mg/m2 3 2,49 0,007 - 0,83 0,054-6,718 [41] 0,022-2,693
Etoposide 100 mg/m2 4 221,76 0,133 - 16,66 9,596-1199,520 [25] 0,043-5,409
Other Asparaginase 30000 IU/m2 8 26,56 0,033 - 4,17 2,400-299,952 [42] 0,090-11,294
Bortezomib 1.45 mg/m2 40 21,62 0,007 - 0,83 0,480-59,976 [43] 0,022-2,774
Prednisolone 1 mg/kg/day 3 41.58 0,16666 - 20,83 11,998-1499,760 [44] 0,289-36,069
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Table 2 The average Mean Cell Survival (MCS) of the eleven body cavity lymphoma cell lines at different drug
concentrations, expressed as the Q Area Under Curve values (QAUC)
125 × dilution 25 × dilution 5 × dilution 1 × dilution 125 × dilution 25 × dilution 5 × dilution 1 × dilution
Effective
drugs
Chlorambucil Epirubicin
MCS 14.8560 46.6236 80.8708 84.7608 MCS 19.2643 37.3816 63.5034 85.1459
SD 15.3967 12.9966 21.0326 22.0111 SD 14.6115 16.3379 19.2617 26.7694
QAUC 1,4285 7,1426 35,7129 178,5643 QAUC 0,0016 0,0079 0,0397 0,1985
Paclitaxel Dactinomycin
MCS 17.0131 45.1537 67.7781 89.5709 MCS 7.9351 36.0115 67.0155 86.7944
SD 24.0155 49.5533 35.9258 22.0081 SD 8.4436 31.4395 26.8592 24.4412
QAUC 0,0037 0,0185 0,0927 0,4636 QAUC 0,0267 0,1336 0,6679 3,3397
Daunorubicin Docetaxel
MCS 20.7690 27.3619 63.7950 87.2387 MCS 19.7376 21.9731 37.6060 59.5325
SD 25.0224 24.1810 31.5421 23.0699 SD 21.0333 20.3415 21.1706 27.0225
QAUC 0,0045 0,0226 0,1129 0,5643 QAUC 0,1923 0,9616 4,8081 24,0404
Vinorelbine Vinblastin
MCS 18.1346 20.5045 40.0830 53.0230 MCS 26.8433 40.9968 67.9391 81.0989
SD 16.8776 21.5082 22.6266 26.5102 SD 32.9835 31.9132 33.5183 17.2183
QAUC 0,0096 0,0481 0,2404 1,2020 QAUC 0,0281 0,1404 0,7020 3,5100
Asparaginase Fluorouracil
MCS 33.4151 62.3275 90.6113 94.4347 MCS 41.1156 58.9125 70.3122 83.0342
SD 25.9953 34.9567 26.1363 23.3606 SD 19.1314 27.2339 23.4010 19.8986
QAUC 0,0903 0,4517 2,2587 11,2937 QAUC 0,3463 1,7313 8,6566 43,2831
Etoposide Doxorubicin
MCS 30.6138 50.2125 64.2707 74.6943 MCS 29.0927 66.8651 77.2076 80.7702
SD 20.8709 23.8410 23.6330 19.0535 SD 19.1960 25.0111 26.0959 27.3229
QAUC 0,0433 0,2164 1,0818 5,4091 QAUC 0,0009 0,0044 0,0219 0,1095
Gemcitabin Methotrexate
MCS 31.4369 45.9785 58.4073 67.9991 MCS 47.1542 44.9205 70.0761 84.2659
SD 33.0357 38.5124 37.0529 36.6568 SD 22.4628 21.6895 25.4751 25.4385
QAUC 0,0495 0,2473 1,2367 6,1837 QAUC 0,0192 0,0962 0,4810 2,4050
Vincristine Topotecan
MCS 43.8400 69.1932 80.2086 81.6665 MCS 41.8048 75.3319 84.1050 90.7907
SD 34.7208 35.8971 29.9816 32.6203 SD 16.4675 24.5366 25.2812 25.3696
QAUC 0,3091 1,5455 7,7273 38,6364 QAUC 0,0215 0,1077 0,5385 2,6926
Non-
effective
drugs
Bortezomib Bleomycin
MCS 79.4105 66.8656 68.2865 64.8357 MCS 60.3729 69.3422 76.5090 80.8431
SD 25.4732 25.6668 28.0206 24.9547 SD 16.7323 18.8710 22.7197 16.8950
QAUC 0,0222 0,1110 0,5548 2,7739 QAUC 0,0173 0,0866 0,4330 2,1650
Cladribine 6-mercaptopurin
MCS 81.0033 82.0998 84.1061 92.0852 MCS 74.0197 87.8677 97.1334 98.2332
SD 21.2666 22.0174 20.1630 21.3224 SD 28.3769 23.3376 30.0858 25.3860
QAUC 0,0846 0,4231 2,1156 10,5778 QAUC 0,2886 1,4429 7,2146 36,0729
Oxaliplatin Cytarabine
MCS 87.0156 89.3148 82.6868 86.8853 MCS 69.9787 77.2199 83.5057 89.0542
SD 30.3307 26.7413 24.1939 25.6311 SD 31.2151 36.2648 38.6377 32.5155
QAUC 0,0089 0,0444 0,2218 1,1090 QAUC 0,0433 0,2164 1,0818 5,4091
Prednisolone Mitomycin
MCS 98.9838 99.8113 95.6985 92.9011 MCS 73.4043 79.2375 80.0565 79.4133
SD 12.7979 15.5728 14.2013 14.0330 SD 28.5533 19.7620 18.7334 19.3133
QAUC 0,2886 1,4428 7,2139 36,0693 QAUC 0,0714 0,3571 1,7857 8,9286
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clinical dose and half-time using the standard trapezoi-
dal rule calculation. The in vivo AUC72 hr data is sum-
marized in the seventh column of Table 1. The detailed
references to the clinical dose and to the in vivo half-
time data are available at the Swedish pharmacological
website http://fass.se. A QAUC72 hr value higher than 1
indicates that the in vitro drug concentration is higher
than the one used in the clinical practice. If this value is
1, it means that the in vitro concentration corresponds
to the clinically achieved in vivo concentration.
Results
The in vitro drug sensitivity assay
We have tested the drug sensitivity patterns of the body
cavity lymphoma lines in short term, in vitro survival
assays. The clinical origin and viral status of the indivi-
dual lines is summarized in Figure 1. Each cell line was
tested against 27 different drugs, in triplicates, at four
different concentrations. The assay was carried out on
384 well plates. After 3 days of incubation each indivi-
dual well of the test plates was photographed using a
custom developed, automated extended field confocal
microscope. Living and dead cells were differentially
stained using viability dependent fluorescent dyes as
shown in Figure 2. Each individual living or dead cell
was identified counted and their fluorescence intensity
distribution was recorded using automated image analy-
tic and quantitation programs. For each well the percen-
tage of surviving cells was calculated by comparing the
number of living cells in the given well to the average of
living cells in the untreated control wells.
The summarized drug sensitivity pattern of the body
cavity lymphoma cell lines
The summarized cell survival data is shown in Figure 3.
The middle line of the individual curves represents the
Mean Cell Survival (MCS) for all the cell lines along
with the ± Standard Deviations of the means (SD - gray
shaded area) for the four different dilutions of the 27
drugs. Drugs were considered to be more universally
active if they showed less standard deviation around the
means.
Most of the lines were sensitive for sixteen of the 27
drugs where sensitivity was defined as less than 50%
mean survival at any of the drug dilutions (effective
drugs). If more than half of the cells were alive even at
the highest concentration than the drug was considered
to be ineffective.
We found that the sixteen effective drugs against
body-cavity lymphoma were the following in the order
of effectiveness: Dactinomycin, Chlorambucil, Paclitaxel,
Vinorelbine, Epirubicin, Docetaxel, Daunorubicin, Vin-
blastin, Doxorubicin, Etoposide, Gemcitabine, Asparagi-
nase, Fluorouracil, Topotecan, Vincristine and
Methotrexate.
Most body-cavity lymphoma lines were resistant to
Oxaliplatin, Bleomycin, 6-Mercaptopurine, Hydro-
xyurea, Cladribine, Carboplatin, Bortezomib, Cytosine-
arabinosid, Prednisolone, Mitomycin and Fludarabin.
Although the Oxaliplatin, Cisplatin and Prednisolone
drugs were not effective against any of the body-cavity
lymphoma lines these drugs show concentration-
dependent growth-inhibitory effect on other cell lines
or primary tumors in parallel experiments (data not
shown) at the same concentration as used in this
paper [18].
Heat map of the cluster analysis
In order to identify possible co-segregation of the sensi-
tivity patterns of the individual drugs as well as to sys-
tematically compare all the lines with each other, we
have carried out unsupervised two-dimensional hier-
archical clustering of the simplified drug sensitivity data
using the Cluster 3.0 program for MacOS X. The results
were visualized using the program TreeView [19]. The
sensitivity to the drug was represented on a 5 step scale
where every step represents less than 50% viability at
the four different drug dilutions. (Resistant - if more
than 50% survival at the highest concentration, maxi-
mum sensitivity - if less than 50% survival at the lowest
concentration.) The graphical representation of the clus-
tering results, along with the EBV, HIV status and the
presence of concomitant Kaposi sarcoma, are shown in
Figure 1.
Table 2 The average Mean Cell Survival (MCS) of the eleven body cavity lymphoma cell lines at different drug concen-
trations, expressed as the Q Area Under Curve values (QAUC) (Continued)
Hydroxyurea Carboplatin
MCS 88.8788 86.3322 97.5959 98.8578 MCS 113.3868 103.2988 113.4341 110.1786
SD 21.5473 19.8568 17.5610 18.7218 SD 39.2983 27.4344 43.5238 38.6427
QAUC 0,0381 0,1904 0,9522 4,7611 QAUC 0,0007 0,0036 0,0180 0,0902
Fludarabine
MCS 67.0129 76.1851 79.2040 95.8649
SD 43.0343 35.3340 37.6906 19.6811
QAUC 0,4329 2,1645 10,8223 54,1117
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Figure 1 Heat map representation of the hierarchical clustering of the simplified drug sensitivity data of the individual cell lines
against all the drugs along with the presence of EBV in the cell lines, the HIV status and the age of the patients and the anatomical
location of the founder sample (A - ascites, P - pleural effusion, B - blood). Intensity of the color shows the scale of the sensitivity. Black is
resistant, brightness of the red color is proportional to the effectiveness of the drug.
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Pharmacokinetic comparison
Absolute drug sensitivity values have relatively little clin-
ical relevance if they are not correlated with clinically
achievable in vivo concentrations. In order to analyze
the data in relation to the pharmacokinetic behavior of
the given drugs we have plotted the mean survival
values as the function of the Quotient of the Area
Under Curve (QAUC72 hr) values of the particular
drugs. The QAUC72 hr values of a drug were created by
dividing the calculated in vitro AUC72 hr values by the
in vivo achievable AUC values (which were calculated
from clinical dose and half-time). As shown in Figure 4.
most drugs were tested in the pharmacologically most
relevant range of QAUC72 hr (close to 1).
Plotting the mean cell survival for each individual
drug against a common QAUC72 hr axis shows that
Daunorubicin, Epirubicin, Paclitaxel and Vinorelbine
were the most effective drugs (low survival at low
QAUC72 hr values). Moreover most body cavity lym-
phoma lines were sensitive to these drugs. Importantly,
Doxorubicin, the only antracyclin drug that is currently
included in chemotherapy protocols against body cavity
lymphomas showed a rather heterogeneous effect. Two
of the eleven lines were highly sensitive for Doxorubicin
whereas two were completely resistant at the maximum
drug concentration that we could reach in the current
assay (QAUC = 0.11). The two lines (JSC-1 and BC-3)
were, in general, the least sensitive for chemotherapeutic
drugs, however were still sensitive for Daunorubicin,
Epirubicin and Vinorelbine.
Dactinomycin showed the highest killing efficiency in
the present in vitro assay. The calculation of the
QAUC72 hr value for the corresponding Dactinomycin
concentration however revealed that the concentration
that was required for the high killing effect is higher
than the levels that are realistically achievable in a
patient.
When treating the body-cavity lymphoma cells with
Carboplatin at low QAUC72 hr values, a relative increase
in the number of surviving cells was observed as com-
pared to non-treated controls. The survival was above
100% in case of all the 11 lines suggesting that low dose
Carboplatin protected from spontaneous cell death.
Discussion
In vitro growing cell lines are the closest model sys-
tems available today for studying the biological features
of body cavity lymphomas. The cell lines that were
used in the present study represent a variety of differ-
ent origin. The investigation included cell lines estab-
lished from ascites fluid, pleural effusion or from the
peripheral blood of PEL patients. Despite their differ-
ent origin, the body-cavity lymphoma lines showed a
remarkably similar sensitivity pattern for a number of
drugs. Only one cell line was highly resistant for most
of the drugs (JSC1) whereas two cell lines (BC1 and
BCBL-1) showed increased overall sensitivity to most
of the drugs.
Figure 2 In vitro drug resistance of body cavity cell lines was
assessed using a 3 day survival assay on microtiter plates on
single cell level. The top panel shows the 384 well plates, the
colored area shows the drugs, each at 4 different concentrations in
triplicates. The highest concentrations are on the left and each
adjacent column represents a 5-fold serial dilution. The middle
panel is the magnification of a mosaic of microscopic images of six
wells treated with the dilution series of one drug. The living and
dead cells were differentially stained using fluorescent dyes as
shown in yellow and blue colors on the digitally colored images.
The bottom panel shows a close-up of a single microscopic field
within one well.
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The presented data suggests that, for a number of
cytostatic drugs the body cavity lymphoma cell lines
share a common cytotoxic drug sensitivity profile. These
profiles show no obvious correlation with the biological
or clinical features of the lymphomas. Clustering of the
drug sensitivity data revealed that the profiles are inde-
pendent of the EBV status, anatomical localization of
the lesion, the age the patient or the rapidity of the
Figure 3 Mean values and standard deviations of drug sensitivity of eleven body cavity cell lines for 27 different cytostatic drugs; x
axis: increasing concentrations of the drug, y axis: fraction of surviving cells 0-100%. The drug was considered to be effective if the
survival was below 50% at least at one concentration. Non-effective drugs: survival is above 50% even at the highest concentration.
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progression of the disease. The two cell lines (BCP-1
and BC-3) that arouse from HIV negative patients
showed relatively low drug sensitivity.
The current treatment alternative is a combination of
Methotrexate with CHOP (Cyclophosphamide, Doxoru-
bicin, Prednisolone, Vincristine)-regimes. The present
data showed that the cell lines exhibit varying sensitivity
to Methotrexate and Vincristine and are completely
resistant to Prednisolone.
Cyclophosphamide or Ifosphamide were not tested on
the body cavity lymphoma lines, because both of these
compounds are prodrugs that have to be converted into
active metabolites by the liver in vivo.
It has been reported that the proteasome inhibitor
Bortezomib induces apoptosis of the cell lines BCBL-1
and BCP-1 in vitro [13]. In this study only BCBL-1
showed detectable sensitivity to Bortezomib and only at
the highest concentration whereas all the other lines
were resistant.
In the present study body cavity lymphoma lines
showed considerable sensitivity for anti-microtubule
drugs and anthracyclins. Importantly all lines were sen-
sitive to Epirubicin and Vinorelbine even at low
QAUC72 hr values. Epirubicin required tenfold lower
concentration than the in vivo achievable concentration
to kill more than 80% of the cells for most of the lines.
Epirubicin is primarily used against breast and ovarian
cancer, gastric cancer, lung cancer and lymphomas, but
has not yet been tested against body cavity lymphomas
[20].
In summary, the analysis of drug sensitivity profiles of
the available body cavity lymphoma lines against 27
commonly used drugs revealed considerable heterogene-
ity in drug response. Four drugs, namely, Daunorubicin,
Epirubicin, Paclitaxel and Vinorelbine showed uniformly
high efficiency on the cell lines. These drugs are not yet
included in the current chemotherapy protocols of body
cavity lymphomas. The heterogeneity of drug response
also suggests that optimal care of the lymphoma
patients would include the determination of drug sensi-
tivity patterns of the primary tumor samples and that
these patients would benefit from assay guided indivi-
dualized therapy.
Conclusions
We suggest that inclusion of the above drugs into PEL
chemotherapy protocols may be justified. The heteroge-
neity in the drug response pattern however indicated
Figure 4 Drug sensivity mean values of the survival of the body cavity lymphoma lines, plotted against QAUC72 hrs values identify
Epirubicin, Daunorubicin, Vinorelbine and Paclitaxel as novel candidate drugs against body cavity lymphomas.
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that assay guided individualized therapy might be
required to optimize therapeutic response.
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